Solution for injection 1 mg/2 ml
Trade name: Vincristine – Belmed.
International nonproprietary name: Vincristine.
Description: clear, colorless or light yellow solution.
Composition: each vial contains:
Active substance: vincristine sulfate 0.5 mg (1 ml vial) or 1 mg (2 ml vial);
Excipients: mannitol (E421), sulfuric acid (E513), sodium hydroxide (E524), water for injection.
Pharmaceutical form: solution for intravenous administration.
Pharmacotherapeutic group: Antineoplastic drugs.
Vinca alkaloids and their analogues.
ATC code: L01CA02.
Indications for use:
► Leukemia, including acute lymphocytic leukemia, chronic lymphocytic leukemia, acute myeloblastic leukemia and blast crisis of chronic myelogenous leukemia.
► Malignant lymphomas, including Hodgkin’s disease and non-Hodgkin’s lymphoma.
► Multiple myeloma.
► Solid tumors, including breast cancer, small cell lung cancer, head and neck tumors and soft tissue sarcoma.
► Solid tumors of children, including Ewing’s sarcoma, embryonic rhabdomyosarcoma, neuroblastoma, Wilms tumor, retinoblastoma and medulloblastoma.
► Idiopathic thrombocytopenic purpura (with resistance to corticosteroids and ineffectiveness of splenectomy). It is not recommended to use vincristine as a first- line preparation. The recommended weekly doses of vincristine from 3 to 4 weeks in some patients led to a stable remission. If the patient does not respond to vincristine after 3 to 6 doses, then the probability of positive dynamics for additional doses is small.
